X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (604) 604
humans (502) 502
aptamers, nucleotide - therapeutic use (205) 205
animals (202) 202
aptamer (193) 193
aptamers (166) 166
vascular endothelial growth factor a - antagonists & inhibitors (158) 158
aptamers, nucleotide - chemistry (147) 147
ranibizumab (139) 139
aptamers, nucleotide - administration & dosage (135) 135
ophthalmology (132) 132
male (118) 118
female (117) 117
bevacizumab (115) 115
aptamers, nucleotide - adverse effects (114) 114
pharmacology & pharmacy (113) 113
macular degeneration (111) 111
macular degeneration - drug therapy (100) 100
cancer (99) 99
nanoparticles (93) 93
endothelial growth-factor (88) 88
chemistry, analytical (85) 85
dna (85) 85
aged (81) 81
pegaptanib (80) 80
ligands (76) 76
biochemistry & molecular biology (75) 75
treatment outcome (75) 75
antibodies, monoclonal, humanized (74) 74
drug delivery systems (73) 73
vascular endothelial growth factor (72) 72
biotechnology & applied microbiology (70) 70
deoxyribonucleic acid--dna (69) 69
rna (69) 69
analysis (68) 68
middle aged (68) 68
proteins (68) 68
aptamers, nucleotide - pharmacology (67) 67
angiogenesis inhibitors - therapeutic use (65) 65
aptamers, nucleotide - metabolism (65) 65
intravitreal injections (64) 64
drugs (61) 61
health aspects (60) 60
research (60) 60
therapy (60) 60
in-vitro selection (59) 59
physiological aspects (57) 57
angiogenesis inhibitors - adverse effects (55) 55
cell line, tumor (54) 54
medicine, research & experimental (54) 54
mice (53) 53
nanoscience & nanotechnology (53) 53
selex aptamer technique (53) 53
aged, 80 and over (52) 52
care and treatment (51) 51
antibodies, monoclonal - therapeutic use (50) 50
choroidal neovascularization - drug therapy (48) 48
in-vivo (48) 48
biophysics (47) 47
article (46) 46
ribonucleic acid--rna (46) 46
angiogenesis inhibitors - administration & dosage (45) 45
drug therapy (45) 45
in-vitro (45) 45
injections (45) 45
binding (44) 44
review (44) 44
vitreous body (44) 44
base sequence (43) 43
electrochemistry (43) 43
oligonucleotides (43) 43
selex (43) 43
aptamers, nucleotide - genetics (41) 41
biosensor (41) 41
biosensors (41) 41
gene expression (41) 41
rna aptamers (41) 41
drug-delivery (40) 40
gold nanoparticles (40) 40
macular edema - drug therapy (40) 40
protein binding (40) 40
fluorescence (39) 39
vehicles (39) 39
visual acuity (39) 39
antibodies (38) 38
clinical trials (37) 37
photodynamic therapy (37) 37
abridged index medicus (36) 36
age-related macular degeneration (36) 36
drug delivery (36) 36
hematology (36) 36
nucleic acids (36) 36
cells (35) 35
dna aptamers (35) 35
fluorescein angiography (35) 35
antibodies, monoclonal - adverse effects (34) 34
biosensing techniques - methods (34) 34
chemistry, multidisciplinary (34) 34
chemotherapy (34) 34
diabetic retinopathy - drug therapy (34) 34
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (700) 700
German (11) 11
French (4) 4
Japanese (4) 4
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, pp. CD007419 - CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 12/2006, Volume 114, Issue 23, pp. 2490 - 2497
Journal Article
Circulation, ISSN 0009-7322, 12/2007, Volume 116, Issue 23, pp. 2678 - 2686
Journal Article
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2015, Volume 11, Issue 3, pp. 671 - 679
Journal Article
American Journal of Ophthalmology, ISSN 0002-9394, 2016, Volume 169, pp. 68 - 72
Abstract Purpose To investigate a certain set of methodological limitations in published anti-VEGF randomized controlled trials (RCT). Design Descriptive... 
Ophthalmology | OPHTHALMOLOGY | MANAGEMENT | INTRAVITREAL BEVACIZUMAB | EFFICACY | SAMPLE-SIZE CALCULATIONS | RANIBIZUMAB | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Intravitreal Injections | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Aptamers, Nucleotide - therapeutic use | Drug-Related Side Effects and Adverse Reactions - etiology | Male | Treatment Outcome | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Aptamers, Nucleotide - adverse effects | Drug-Related Side Effects and Adverse Reactions - epidemiology | Randomized Controlled Trials as Topic | Ranibizumab - adverse effects | Angiogenesis Inhibitors - therapeutic use | Female | Angiogenesis Inhibitors - adverse effects | Drug-Related Side Effects and Adverse Reactions - diagnosis | Databases, Factual | Physiological aspects | Medical colleges | Vascular endothelial growth factor | Analysis | Eye diseases | Endothelial growth factors | Cataracts | Diabetic retinopathy | Internal medicine | Funding | Clinical trials | Impact factors | Studies | Macular degeneration | Medicine | Reading | Archives & records | Surgery | Journals | Diabetes | Drug dosages | Research methodology | Age | Index Medicus | Abridged Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 08/2010, Volume 122, Issue 6, pp. 614 - 622
Journal Article
Retina, ISSN 0275-004X, 01/2014, Volume 34, Issue 1, pp. 12 - 17
Journal Article
American Journal of Ophthalmology, ISSN 0002-9394, 2009, Volume 148, Issue 5, pp. 647 - 656
Purpose To evaluate potential safety risks associated with nonspecific inhibition of vascular endothelial growth factor (VEGF). Design A perspective, reviewing... 
Ophthalmology | PHARMACOKINETICS | ADVERSE DRUG EVENTS | BEVACIZUMAB | COLORECTAL-CANCER | VEGF | PEGAPTANIB | OPHTHALMOLOGY | MACULAR DEGENERATION | ARTERIAL THROMBOEMBOLIC EVENTS | PHARMACOVIGILANCE | RANIBIZUMAB | Drug Administration Routes | Receptors, Vascular Endothelial Growth Factor | Medical Records Systems, Computerized | Meta-Analysis as Topic | Recombinant Fusion Proteins - adverse effects | Humans | Antibodies, Monoclonal - adverse effects | Treatment Outcome | Aptamers, Nucleotide - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Aptamers, Nucleotide - adverse effects | Macular Degeneration - drug therapy | Bevacizumab | Antibodies, Monoclonal, Humanized | Angiogenesis Inhibitors - administration & dosage | Choroidal Neovascularization - drug therapy | Antibodies, Monoclonal - administration & dosage | Ranibizumab | Adverse Drug Reaction Reporting Systems - utilization | Product Surveillance, Postmarketing | Registries | Angiogenesis Inhibitors - adverse effects | Recombinant Fusion Proteins - administration & dosage | Databases, Factual | Vascular endothelial growth factor | Safety and security measures | Macular degeneration | Proteins | Studies | Heart attacks | Photodynamic therapy | Disease | Rodents | Clinical trials | Data bases | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
American Journal of Ophthalmology, ISSN 0002-9394, 2011, Volume 152, Issue 2, pp. 266 - 272
Purpose To determine longitudinal rates of ocular complications after anti–vascular endothelial growth factor (VEGF) treatment for neovascular age-related... 
Ophthalmology | INTRAVITREAL INJECTIONS | ENDOPHTHALMITIS | PROPENSITY SCORE | BEVACIZUMAB | SAFETY | CLAIMS | VISUAL IMPAIRMENT | VALIDATION | OPHTHALMOLOGY | RANIBIZUMAB | Retinal Detachment - etiology | Vitreous Hemorrhage - diagnosis | Retinal Perforations - epidemiology | Follow-Up Studies | United States | Humans | Antibodies, Monoclonal - adverse effects | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Endophthalmitis - epidemiology | Endophthalmitis - etiology | Health Services Research | Vitreous Hemorrhage - etiology | Case-Control Studies | Macular Degeneration - drug therapy | Vitreous Hemorrhage - epidemiology | Bevacizumab | Incidence | Antibodies, Monoclonal, Humanized | Retinal Detachment - diagnosis | Ranibizumab | Uveitis - epidemiology | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Eye Diseases - epidemiology | Endophthalmitis - diagnosis | Female | Retinal Perforations - etiology | Retinal Detachment - epidemiology | Retrospective Studies | Uveitis - diagnosis | Intravitreal Injections - adverse effects | Retinal Perforations - diagnosis | Eye Diseases - etiology | Proportional Hazards Models | Aptamers, Nucleotide - adverse effects | Eye Diseases - diagnosis | Medicare Part B - statistics & numerical data | Uveitis - chemically induced | Macular degeneration | Physiological aspects | Care and treatment | Medicare | Vascular endothelial growth factor | Older people | Index Medicus | Abridged Index Medicus
Journal Article